Wilm’s tumor also called Nephroblastoma is a type of cancer that starts in the kidneys and is most common type of kidney cancer in children. The ratio of Wilm’s tumor is about 9 of 10 kidney cancers in children. Tumors which affects only one kidney and have only one tumor are unilateral. Around 5-10% of children with Wilm’s tumors have more than one tumor in same kidney. About 5% of children with Wilm’s tumors have tumors in both kidneys which means they have bilateral disease. Wilm’s tumors often become large, averagely newly found Wilm’s tumor is larger than the kidney in which it is started. Common symptoms present in children are fever and bleeding during urination, abdominal swelling and abdominal pain. In present scenario, survival rate of children suffering from Wilm’s tumor is approximately 80% to 90%. Average age at diagnosis is about 3-4 years and is rare as children grow older and is uncommon after age 6.
Technological advancement owing to rise in enhanced diagnostics and treatment therapies, increasing number of births per year are some of the factors which will drive the Wilm’s tumor market. In addition macro-economic factors like increasing expenditure on research and development to bring out novel therapies for Wilm’s tumor will drive this market in forecast period. Due to the high cost of treatment of therapies this can hamper the overall growth of the Wilm’s tumor market.
The global market for Wilm’s tumor is segmented on basis of types, treatment and regional presence:
The incidence of Wilm’s tumor in children below 15 years is 7.1 cases per 1 million children. It is observed that Wilm’s tumor is slightly more in girls than boys and is especially in Africa and U.S. Factors such as increasing demand for diagnostic solutions and treatment therapies for Wilms tumor, Wilm’s tumor market is expected to have tremendous growth during the forecast period (2016-2026)
On the basis of region presence, abdominal aortic aneurysm treatment market is segmented into five key regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
Analyzing the present scenario North America dominates the global market for Wilms tumor followed by Europe due to the high incidence rate of Wilms tumor. According to the American Society of Cancer in 2015 about 500 new cases of Wilms tumor are diagnosed in the U.S. The Wilms tumor is relatively more in African countries while comparatively less in East Asia.
Many companies have their presence in this market while some of them have their drugs in the pipeline for clinical trials. Some of the key player in Wilm’s Tumor Market are Merck & Co.Inc, MediLexicon International Ltd, Bristol-Myers Squibb, APOTEX INC
The report covers exhaustive analysis on:
Regional analysis includes